Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFORT: Adavosertib with or without Olaparib in PARP-Resistant Ovarian Cancer
NCT03579316Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of adavosertib, ceralasertib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2018; status: active, not recruiting.
02
Drugs
adavosertibceralasertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03579316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579316.